Evidence map›Paper›PMID 37845285›Full record

Trial reportLeukemia2024

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Thomas Pabst, Richard Greil, Paul J Bröckelmann, Max S Topp, Marianne Just and 19 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Classical Hodgkin Lymphoma Today.Mediterranean journal of hematology and infectious diseases · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 16 institutions in 5 countries.

Michael Fuchs *German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Anne Sophie Jacob *German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Helen KaulGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Carsten KobeDepartment of Nuclear Medicine, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-2909-0826
Georg KuhnertNuclear Medicine Siegen I Kreuztal, Siegen, Germany.
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-6055-5257
Richard GreilIIIrd Medical Department, Paracelcus Medical University and Salzburg Cancer Research Institute, Salzburg, Austria.
Paul J BröckelmannGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0001-9662-9900
Max S ToppMedizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Marianne JustDres. med. Just/Düwel/Riesenberg/Steinke/Schäfer, Studiengesellschaft, Bielefeld, Germany.
Bernd HertensteinDepartment of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
Martin SoeklerOnkology, Spital Thun, Switzerland, formerly University of Tübingen, Tübingen, Germany.
Martin VogelhuberMedizinische Klinik III, Universitätsklinik Regensburg, Regensburg, Germany.
Josée M ZijlstraDepartment of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Ulrich Bernd KellerDepartment of Internal Medicine III, Klinikum "Rechts der Isar", Munich, Germany.ORCID http://orcid.org/0000-0002-8485-1958
Stefan W KrauseDepartment of Internal Medicine 5, Haematology/Oncology, Uniklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-5259-4651
Ulrich DührsenDepartment of Haematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Julia MeissnerUniversity of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1908-2096
Andreas ViardotDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Hans-Theodor EichDepartment of Radiotherapy, University Hospital of Muenster, Muenster, Germany.
Christian BauesDepartment of Radiotherapy, University of Cologne, Cologne, Germany.
Volker DiehlGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Andreas RosenwaldInstitute of Pathology, Julius Maximilian University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Ina BuehnenGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Bastian von TresckowGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-1410-4487
Markus DietleinDepartment of Nuclear Medicine, University of Cologne, Cologne, Germany.
Peter BorchmannGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Andreas EngertGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Dennis A EichenauerGerman Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. dennis.eichenauer@uk-koeln.de.ORCID http://orcid.org/0000-0002-1927-3514
University of Cologne · DEAmsterdam University Medical Centers · NLHeidelberg University · DEKlinikum Bremen-Mitte · DEParacelsus Medical University · ATTUM Klinikum · DEUniversitätsklinikum Erlangen · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Münster · DEUniversity Hospital Regensburg · DEUniversity Hospital Ulm · DEUniversity of Bern · CHUniversity of Duisburg-Essen · DEUniversity of Siegen · DEUniversity of Tübingen · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.

Indexed as

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinFollow-Up StudiesHumansNeoplasm StagingPositron Emission Tomography Computed TomographyVinblastineBleomycinDacarbazineDoxorubicinVinblastine

Identifiers

PMID37845285
PMCPMC10776396
OpenAlexW4387665269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.